A 32-year-old man from rural Bihar presents with jaundice, dark urine, and abdominal pain for 5 days. He reports consuming contaminated water 3 weeks ago. On examination: icterus, hepatomegaly, no ascites. ALT 2800 U/L, AST 2200 U/L, bilirubin 8.2 mg/dL (direct 6.8), INR 1.1, albumin 3.8 g/dL. Anti-HAV IgM is positive. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **acute hepatitis A** with: - Typical prodrome (contaminated water, 3-week incubation) - Anti-HAV IgM positive (diagnostic) - Marked transaminitis (ALT > AST, typical of acute viral hepatitis) - **Preserved synthetic function** (INR 1.1, albumin 3.8 g/dL) - No signs of decompensation (no ascites, normal INR) ## Management Principles for Acute Hepatitis A **Key Point:** Acute hepatitis A is **self-limited** in immunocompetent hosts. Management is **supportive**, not antiviral. **High-Yield:** Fulminant hepatic failure (FHF) occurs in <1% of cases overall, but risk increases with age >40 years and underlying cirrhosis. This patient (age 32, no cirrhosis) is at low risk. ### Indications for Admission - INR >1.5 (suggests coagulopathy) - Encephalopathy or altered mental status - Severe coagulopathy or thrombocytopenia - Inability to maintain oral intake - Age >40 years with fulminant features - Immunocompromised state This patient has **none of these**; however, **close monitoring is prudent** given the acute phase and potential for rapid deterioration. ### Why Admission with Daily Monitoring? 1. **INR trend monitoring** — early sign of synthetic dysfunction; INR >1.5 warrants escalation 2. **Bilirubin kinetics** — rising bilirubin despite falling transaminases may indicate cholestasis; persistent elevation >10 mg/dL suggests prolonged course 3. **Clinical deterioration** — encephalopathy, bleeding, or worsening coagulopathy requires immediate intervention 4. **Supportive care optimization** — IV hydration, electrolyte correction, nutritional support **Clinical Pearl:** Acute hepatitis A does NOT require antiviral therapy. Ribavirin is NOT indicated and offers no benefit in immunocompetent hosts. ## Why Each Option Is Correct or Wrong | Aspect | Correct Answer | Why | |--------|---|---| | **Admission** | Yes | Acute phase requires daily INR/bilirubin monitoring; low threshold for detecting FHF | | **Supportive care** | Yes | Mainstay of management; adequate hydration, rest, nutritional support | | **Antiviral therapy** | No | No role in immunocompetent acute HAV; self-limited disease | | **Biopsy** | No | Not indicated in acute hepatitis; risk of bleeding if coagulopathy develops | | **Discharge** | No | Premature; risk of unrecognized deterioration in acute phase | **Mnemonic: "SAFE HAV"** — **S**elf-limited, **A**dmit if high-risk, **F**ulminant monitoring, **E**xpect recovery; **H**epatitis **A** **V**iral — supportive care only. [cite:Harrison 21e Ch 297]